Signant Health provides clinical trial technology and services, focusing on clinical data collection, patient engagement, clinical IP management, and analytics. Signant Health offers tailored solutions to meet specific protocol requirements.

Signant Health

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

James B. Powell

Laboratory Corporation of America Holdings

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings, Inc.

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Metric
Company Name	Signant Health	Laboratory Corporation of America Holdings	Medpace Holdings, Inc.	Charles River Laboratories International, Inc.
Symbol		LH	MEDP	CRL
MSH ID	COM:SIGNANTHEALTH	COM:LABCORP	COM:MEDPACE	COM:CRIVER
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Clinical Research and Development	Medical - Diagnostics & Research	Medical - Diagnostics & Research	Medical - Diagnostics & Research
Country	US	US	US	US
Stage
Employee Count	1.00K	67K	5.80K	20.40K
Website	signanthealth.com	labcorp.com	medpace.com	criver.com
LinkedIn
Founders

Metric
Market Cap		16.89B	12.98B	10.44B
Enterprise Value
Monthly Web Traffic	43.77K			227.44K
Web Traffic Growth	0.55			-0.07
Valuation
Raised Capital				1.30M

Metric
Revenue	12.16B	1.89B	4.13B
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.15B	524.50M	1.50B
EBITDA	1.70B	365.08M	1.03B
Operating Income	1.12B	336.82M	617.26M
Net Income	418M	282.81M	474.62M
EPS	4.80	9.21	9.38
Diluted EPS	4.77	8.88	9.34
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.27	0.29	0.36
Operating Profit Margin	0.09	0.19	0.15
EBITDA Margin	0.14	0.19	0.25
Net Profit Margin	0.04	0.17	0.11
Return on Equity	0.06	0.64	0.14
Return on Assets	0.03	0.18	0.06
Return on Capital Employed	0.09	0.46	0.09

COM:SIGNANTHEALTH

Signant Health

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	28.87	33.19	23.49
P/B Ratio	2.42	19.25	3.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.59	7.05	3.37
EV Multiple	8.77	37.01	10.77

Metric
Days Sales Outstanding	55.66	59.98	69.20
Days Payables Outstanding	25.45	8.29	18.58
Days Inventory Outstanding	19.25		52.84
Operating Cycle	84.65	57.75	121.81
Cash Conversion Cycle	52.97	49.21	101.86
Asset Turnover	0.77	1.14	0.51

Metric
Operating Cash Flow	1.33B	433.37M	683.90M
Free Cash Flow	874.10M	396.73M	365.37M
Cash Flow to Debt	0.26	3.51	0.31
Operating Cash Flow/Sales	0.11	0.27	0.18
Free Cash Flow Yield	0.05	0.04	0.03

Metric
Cash & Equivalents	536.80M	245.45M	276.77M
Accounts Receivable	-75.30M	-48.28M	-33.43M
Inventory	474.60M		380.26M
Goodwill	6.14B	662.40M	3.10B
Debt to Capitalization	0.43	0.44	0.49
Debt to Assets	0.37	0.27	0.44
Current Ratio	1.36	0.53	1.45
Quick Ratio	0.82	0.88	1.37

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.01	0.02
R&D to Revenue
SG&A to Revenue